Cullinan Oncology (NASDAQ:CGEM) Price Target Raised to $26.00

Cullinan Oncology (NASDAQ:CGEM - Free Report) had its target price increased by Jonestrading from $22.00 to $26.00 in a report released on Wednesday, Benzinga reports. Jonestrading currently has a buy rating on the stock.

Several other analysts also recently weighed in on CGEM. William Blair initiated coverage on Cullinan Oncology in a research note on Monday. They set an outperform rating on the stock. BTIG Research lifted their target price on Cullinan Oncology from $20.00 to $30.00 and gave the stock a buy rating in a report on Wednesday. HC Wainwright decreased their target price on Cullinan Oncology from $34.00 to $29.00 and set a buy rating on the stock in a report on Tuesday. Finally, Wedbush initiated coverage on Cullinan Oncology in a report on Thursday, February 15th. They set an outperform rating and a $30.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of Buy and an average price target of $28.75.

Cullinan Oncology Stock Up 1.0 %

Shares of CGEM traded up $0.18 during mid-day trading on Wednesday, hitting $18.06. The stock had a trading volume of 702,320 shares, compared to its average volume of 459,683. The company has a market cap of $777.84 million, a PE ratio of -4.89 and a beta of 0.33. The company's fifty day simple moving average is $17.29 and its two-hundred day simple moving average is $12.60. Cullinan Oncology has a fifty-two week low of $7.64 and a fifty-two week high of $20.62.

Cullinan Oncology (NASDAQ:CGEM - Get Free Report) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.42. Equities analysts expect that Cullinan Oncology will post -3.6 earnings per share for the current year.

Insider Activity

In other Cullinan Oncology news, insider Corrine Savill sold 18,684 shares of the business's stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $12.14, for a total value of $226,823.76. Following the transaction, the insider now owns 165,990 shares in the company, valued at $2,015,118.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have sold 98,684 shares of company stock worth $1,437,624. 8.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CGEM. Public Employees Retirement System of Ohio acquired a new stake in shares of Cullinan Oncology in the second quarter worth about $53,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Cullinan Oncology by 352.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,954 shares of the company's stock worth $50,000 after acquiring an additional 3,859 shares during the period. Point72 Middle East FZE bought a new stake in shares of Cullinan Oncology in the 2nd quarter worth approximately $59,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Cullinan Oncology by 1,331.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,542 shares of the company's stock worth $59,000 after acquiring an additional 6,085 shares during the period. Finally, Royal Bank of Canada raised its holdings in shares of Cullinan Oncology by 499.8% in the 2nd quarter. Royal Bank of Canada now owns 8,991 shares of the company's stock worth $97,000 after buying an additional 7,492 shares in the last quarter. Hedge funds and other institutional investors own 86.31% of the company's stock.

Cullinan Oncology Company Profile

Cullinan Oncology, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.